HRTX

Business Context and Reporting Period

Company: Heron Therapeutics, Inc. (HRTX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Heron is a commercial-stage biotechnology company focused on acute care and oncology. Its portfolio includes ZYNRELEF (postoperative pain), APONVIE (postoperative nausea and vomiting), CINVANTI (chemotherapy-induced nausea and vomiting), and SUSTOL (chemotherapy-induced nausea and vomiting). The company utilizes proprietary Biochronomer drug delivery technology.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Revenue Growth: Net product sales increased 7.4% to $154.9 million. Acute care sales (ZYNRELEF and APONVIE) surged 65.1%, driven by market share gains and new customers. Oncology sales (CINVANTI and SUSTOL) declined 7.8% due to increased gross-to-net adjustments and a decrease in SUSTOL units, partially offset by a 21.8% increase in CINVANTI units.
• Operating Expenses: Total operating expenses decreased slightly to $116.1 million. Research and Development (R&D) expenses dropped 25.5% to $12.4 million, primarily due to personnel terminations in the prior year and reduced asset write-offs. Sales and Marketing expenses rose 4.2% to $49.1 million due to increased ZYNRELEF promotion.
• Debt Restructuring: The company significantly altered its capital structure in 2025. It extinguished $150 million of 2026 Convertible Notes (recording a $5.8 million loss) and amended its Working Capital Facility to increase capacity to $150 million (recording a $5.5 million loss). It also issued $35 million in new 2031 Convertible Notes. Total debt outstanding rose from $25.5 million to $147.1 million.
• Inventory: Inventory levels increased significantly from $53.2 million to $92.7 million, driven by raw material purchases (polymers) to support future ZYNRELEF production. Cost of product sales included $4.6 million in inventory reserves and write-offs.

Guidance, Outlook, and Risks

• SUSTOL Wind-Down: Management intends to wind down the commercialization of SUSTOL over the next 12 months while evaluating potential product updates. A reintroduction is possible as early as late 2027.
• Liquidity: Management believes existing cash and investments ($46.6 million) are sufficient to meet anticipated cash requirements for at least one year from the filing date.
• Reimbursement: ZYNRELEF continues to qualify for separate Medicare reimbursement under the NOPAIN Act through December 31, 2027. A new permanent J-code was approved effective October 1, 2025.
• Intellectual Property Litigation:
  • Fresenius Kabi: The company won a summary judgment regarding CINVANTI patents in December 2024, blocking generic approval until 2035. Fresenius Kabi has appealed.
  • Mylan: Settled litigation regarding CINVANTI and APONVIE, granting Mylan a license to market generics beginning June 1, 2032.
  • Azurity/Slayback: Litigation regarding CINVANTI is ongoing; a bench trial concluded in November 2025 with post-trial briefing completed in February 2026.
  • Baxter: Filed a complaint in December 2025 regarding a generic CINVANTI ANDA.
• Risks: Key risks include dependence on a limited number of products, potential inventory write-downs, supply chain disruptions from single-source vendors, and the impact of healthcare reform on pricing and reimbursement.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the new minimum cash, revenue, and EBITDA covenants under the amended Working Capital Facility Agreement.
• Patent Expirations: Confirm the status of the Fresenius Kabi appeal and the timeline for the Azurity/Slayback trial decision, as these directly impact the exclusivity period for CINVANTI.
• Inventory Valuation: Monitor the $92.7 million inventory balance, particularly the $59.3 million in raw materials, for potential future write-downs if ZYNRELEF demand does not materialize.
• SUSTOL Strategy: Track the progress of the SUSTOL wind-down and the feasibility of the proposed 2027 reintroduction.
• Cash Burn: Assess the sustainability of the $46.6 million cash position against the increased interest expense from the new debt structure and the $19.0 million in near-term purchase obligations.